|
LYMPHOPROLIFERATIVE SYNDROME 2
|
0.720 |
Biomarker
|
disease |
BEFREE |
CD27 is a co-stimulatory molecule of T cells, and inherited CD27 deficiency is characterized by high susceptibility to EBV infection, though the underlying pathological mechanisms have not yet been identified.
|
28011863 |
2017 |
|
LYMPHOPROLIFERATIVE SYNDROME 2
|
0.720 |
Biomarker
|
disease |
BEFREE |
We sought to identify novel mutations in TNFRSF7/CD27 and to provide an overview of clinical, immunologic, and laboratory phenotypes in patients with CD27 deficiency.
|
25843314 |
2015 |
|
LYMPHOPROLIFERATIVE SYNDROME 2
|
0.720 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
We sought to identify novel mutations in TNFRSF7/CD27 and to provide an overview of clinical, immunologic, and laboratory phenotypes in patients with CD27 deficiency.
|
25843314 |
2015 |
|
LYMPHOPROLIFERATIVE SYNDROME 2
|
0.720 |
GeneticVariation
|
disease |
UNIPROT |
Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27.
|
22801960 |
2013 |
|
LYMPHOPROLIFERATIVE SYNDROME 2
|
0.720 |
GeneticVariation
|
disease |
UNIPROT |
CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia.
|
22197273 |
2012 |
|
LYMPHOPROLIFERATIVE SYNDROME 2
|
0.720 |
GermlineCausalMutation
|
disease |
ORPHANET |
CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia.
|
22197273 |
2012 |
|
LYMPHOPROLIFERATIVE SYNDROME 2
|
0.720 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
LYMPHOPROLIFERATIVE SYNDROME 2
|
0.720 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Combined immunodeficiency
|
0.310 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Novel mutations in TNFRSF7/CD27: Clinical, immunologic, and genetic characterization of human CD27 deficiency.
|
25843314 |
2015 |
|
Combined immunodeficiency
|
0.310 |
Biomarker
|
disease |
BEFREE |
Since homozygosity mapping and exome sequencing did not reveal additional modifying factors, our findings suggest that lack of functional CD27 predisposes towards a combined immunodeficiency associated with potentially fatal EBV-driven hemo-phagocytosis, lymphoproliferation, and lymphoma development.
|
22801960 |
2013 |
|
Cachexia
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Molecular analysis of xenograft models of human cancer cachexia--possibilities for therapeutic intervention.
|
17878525 |
2007 |
|
Alcoholic Liver Diseases
|
0.200 |
Biomarker
|
group |
RGD |
Effect of tea polyphenol on cytokine gene expression in rats with alcoholic liver disease.
|
16698589 |
2006 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The proposed design was developed to address objectives in an early-phase trial of cancer vaccines in combination with agonistic antibodies to CD40 and CD27.
|
31807879 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, these findings suggest that the CD70-CD27 pathway enhances the malignant phenotypes of MPM and diminishes anti-tumor immune response in patients with these neoplasms.
|
31639216 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD70-CD27 pathway-modulating therapies may be applied to CRC patients regardless of their tumor MMR status.
|
30980190 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, we review key literature describing progress in elucidating the efficacy and mode of action of OX40- and CD27-targeting mAbs in preclinical models and provide an overview of current clinical trials targeting these promising receptor/ligand pairings in cancer.
|
29118006 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, we show that a clinically relevant anti-human CD27 mAb, varlilumab, similarly synergizes with PD-L1 blockade for protection against lymphoma in human-CD27 transgenic mice.<b>Conclusions:</b> Our findings suggest that suboptimal T-cell invigoration in cancer patients undergoing treatment with PD-1 checkpoint blockers will be improved by dual PD-1 blockade and CD27 agonism and provide mechanistic insight into how these approaches cooperate for CD8<sup>+</sup> T-cell activation.<i>Clin Cancer Res; 24(10); 2383-94.©2018 AACR</i>.
|
29514845 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Based on supportive preclinical data, we hypothesised that the addition of varlilumab (an anti-CD27 mAb) to rituximab (an anti-CD20 mAb) can improve the rate, depth and duration of the response of rituximab monotherapy in patients with relapsed or refractory B-cell malignancies.
|
30413184 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The protein expression of CD27 quantified with ELISA had a strong correlation with its mRNA expression in NSCLC tumors (Spearman coefficient = 0.494, P < 0.0088).
|
29861409 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, the CD70-CD27 pathway appears to be a crucial component of EBV-specific T cell immunity and more generally for the immune surveillance of B cells and may be a target for immunotherapy of B cell malignancies.
|
28011863 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This review will discuss how the costimulatory molecule CD27 sculpts immunity and preclinical/clinical data indicating its potential for cancer immunotherapy and its clinical translation.
|
28319731 |
2017 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We therefore generated a cytoplasmic deletion mutant of CD27 (CD27-trunc) to study the role of CD70 reverse signaling in the immunosurveillance of B-cell malignancies in vivo.
|
28495792 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A homologous, all murine anti-CD70 CAR model was also used to assess treatment-related toxicities.<b>Results:</b> The CAR consisting of the extracellular binding portion of CD27 fused with 41BB and CD3-zeta (trCD27-41BB-zeta) conferred the highest IFNγ production against CD70-expressing tumors <i>in vitro</i>, and NSG mice bearing established CD70-expressing human tumors could be cured by human lymphocytes transduced with this CAR.
|
27803044 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This review focuses on the role of CD27 co-stimulation in anti-viral T-cell immunity and discusses clinical studies utilising the CD27 co-stimulation pathway for anti-viral, anti-tumour and autoimmune immunotherapy.
|
28086150 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD27 and CD40 costimulatory molecules and TILs expressing activation marker CD38 in the tumour were also correlated with patient survival.
|
26669617 |
2017 |